Blinding {17a}
This trial is a double-blind study. The statistician will label the placebo and gabapentin containers with unique alphanumeric codes (e.g., AA1) which are generated by a computerized random sequence generator. The capsules, the packets, and the labels will look the same. The investigators and the enrolled patients will not be aware of the contents of the capsules.